Literature DB >> 25466476

Overexpression of S100A4 as a biomarker of metastasis and recurrence in oral squamous cell carcinoma.

Jayalakshmi Natarajan1, Keith Hunter2, Vimi S Mutalik3, Raghu Radhakrishnan1.   

Abstract

UNLABELLED: S100A4, a biomarker of epithelial mesenchymal transition (EMT), plays an important role in invasion and metastasis by promoting cancer cell motility. In oral squamous cell carcinoma (OSCC), metastasis results in 90% of cancer associated mortality.
OBJECTIVE: To investigate the role of S100A4 expression as an important component of the epithelial mesenchymal transition (EMT) program in oral squamous cell carcinoma (OSCC).
MATERIAL AND METHODS: S100A4 protein expression was assessed semi-quantitatively by immunohistochemistry in 47 histologically confirmed cases of oral squamous cell carcinoma (OSCC) and 10 normal oral mucosal biopsies. The association between the S100A4 overexpression and the aggressive features of OSCC were analyzed by X2 test.
RESULTS: Moderate to strong cytoplasmic expression of S100A4 was observed in 30 out of 47 specimens of OSCC (64%). Overexpression of S100A4 was significantly associated with the clinical stage, lymph node involvement, metastases, pattern of invasion and recurrence (p<0.05).
CONCLUSION: S100A4 expression represents an important biomarker of prognostic significance that may be used to identify a subset of patients at high risk of invasion and metast.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25466476      PMCID: PMC4245755          DOI: 10.1590/1678-775720140133

Source DB:  PubMed          Journal:  J Appl Oral Sci        ISSN: 1678-7757            Impact factor:   2.698


INTRODUCTION

Initiation and early growth of primary epithelial cancers, and acquisition of invasiveness is thought to herald the advanced stages of this multistep process that eventually leads to metastatic dissemination, with life-threatening consequences[11]. The genetic control and biochemical mechanisms underlying the acquisition of the invasive phenotype are mediated by the activation of an epithelial mesenchymal transition (EMT) program[13]. EMT is a biologic process that allows an epithelial cell to acquire the properties of a mesenchymal cell, thereby promoting invasion into the surrounding stroma and intravasation of tumor cells[27]. A number of distinct molecular markers are engaged in order to initiate EMT and enable its completion. One such marker is the S100A4, a flament-associated calcium-binding protein, which is associated with the cells of mesenchymal origin, and deemed to play a significant role in EMT[7]. S100A4 expression levels strongly correlate with motility, which is a central element of the metastatic cascade[25]. In oral squamous cell carcinoma (OSCC), metastasis results in 90% of cancer associated mortality. In this work, we studied the role of S100A4 in oral cancer as a biomarker of metastasis by assessing its expression in primary tumors from all the clinical stages of oral cancer and determined the association of S100A4 expression with aggressive clinico-pathological parameters including the pattern of invasion, distant metastasis and recurrence. Assessment of S100A4 in oral cancer may be related to the phenotypic alteration and thereby predict its metastatic potential.

MATERIAL AND METHODS

Patient details

The material for present study included a total of 57 formalin fixed paraffin embedded tissue sections retrieved from the departmental archives. Out of these, 47 were patients with carcinoma of the bucco-alveolar mucosal complex and of the foor of the mouth. fhe remaining 10 were healthy mucosal tissues, which were obtained at the time of extraction of impacted teeth. Only surgically treated cases of oral squamous cell carcinoma (OSCC) with a minimum follow-up period of 5 years were included in the study. Institutional Ethics Committee approval (IEC 36/2012) was obtained from Kasturba Hospital, Manipal, prior to carrying out the study. The patient demographics and other details of the cases included in the study are presented in Table 1. A chart analysis was carried out to study the expression of S100A4 in all these cases by immunohistochemistry (IHC). Tissue sections obtained from the lymph node constituted the positive control.
Table 1

The demographic variable of the cases included in the study

ParticularsSubsetNumber(%)Total
GenderMale3778.7247
 Female1021.28 
SiteBuccal mucosa2144.6847
 Alveolus1838.30 
 Floor of the mouth817.02 
PresentationUlceroproliferative2655.3247
 Ulcer817.02 
 Exophytic817.02 
 Swelling510.64 
HabitSLT2655.3247
 ST1225.53 
 SLT + ST36.38 
 NT612.77 

SLT - Smokeless tobacco. S - Smoking tobacco. NT- No tobacco

The demographic variable of the cases included in the study SLT - Smokeless tobacco. S - Smoking tobacco. NT- No tobacco

Immunohistochemistry

Immunohistochemical staining was carried out using indirect streptavidin biotin immunoperoxidase technique. The antibodies and reagents were obtained from Sigma – Aldrich Co. (St. Louis, MO, USA). Sections of 4 μm thickness taken on amino propyl triethoxysilane (APES) coated slides were incubated overnight at 48°C in a slide warmer to ensure complete adhesion of sections. Following tissue sections deparaffinization and hydration through descending grades of alcohol, sections were placed in phosphate buffered saline (PBS) for 30 minutes. The slides were immersed in a microwave resistant plastic staining jar containing antigen retrieval solution (10 mM sodium citrate buffer, pH 6.0) and maintained at 700 W power for 10 minutes. Subsequently, the solution was allowed to cool at room temperature for at least 20 minutes. The slides were incubated in 3% hydrogen peroxide for 5 minutes at room temperature, following which slides were washed with PBS. To decrease the background staining due to nonspecific binding of antibodies, the slides were incubated with 5% bovine serum albumin (BSA) for 10 minutes at room temperature and washed with PBS for 5 minutes. The researchers applied 100 μL of the primary antibody (Rabbit polyclonal anti-S100A4 antibody, 1:250) over the section completely, which was incubated for 60 minutes at 37°C in a humidified chamber. The slides were rinsed with PBS and placed in the PBS bath for 5 minutes. After draining and wiping of the slides, sections were incubated in 100 μl of biotinylated secondary antibody, Anti-Rabbit IgG (whole molecule - Peroxidase antibody produced in goat) for 30 minutes at 37°C. The slides were washed with PBS and placed in PBS bath for 5 minutes. For visualization, sections were incubated with freshly prepared substrate solution (SIGMAFAST™ 3, 3'-Diaminobenzidine tablets) for 5-10 minutes. This was followed by washing the slides in running tap water and counter staining with Mayer's haematoxylin (MHS1- Haematoxylin Solution, Mayer's 1 gil certified hematoxylin *pH 2.4) for 5 minutes, after which the slides were washed in running tap water for 1 minute. Briefy, the sections were dehydrated through ascending grades of alcohol (70%, 95% and 100%) for 2 minutes each, cleared in xylene for 1 minute, mounted in a resinous media and coverslipped.

Staining interpretation

The neoplastic cell with cytoplasmic staining was viewed at 200× magnification, using a light microscope. The distribution of immunolabelling in neoplastic epithelial cells was determined from a minimum of five representative high-power fields at the invasive front. A positive cell demonstrated a diffuse brown signal in the cytoplasm, independent of its intensity. To eliminate any inter-observer bias, the scoring was carried out independently by two observers. The degree of staining for S100A4 was evaluated using a semi-quantitative scale29. Tissues were graded as absent (-) when there was no staining, low (1+) when less than 25% of the tumor cells were positive, moderate (2+) when 25 to 75% of the tumor cells stained positively and diffuse (3+) when more than 75% of the tumor cells were positive for S100A4. S100A4 expression was then correlated with clinicopathological parameters including primary tumor site, stage of tumor, degree of differentiation, lymph node metastasis and mode (pattern) of invasion[28].

Statistics

Statistical analysis was carried out using SPSS version 16.0 for Windows. Kendall's tau-b statistics was applied to assess the measure of agreement between two observers. Chi-square test was used to study the association between the S100A4 staining and clinicopathological parameters. Results were considered statistically significant if p<0.05.

RESULTS

Positive S100A4 expression in the cytoplasm of the tumor cells was observed in 30 out of 47 cases (63.82%) of OSCC. Kendall's tau-b test between the two observers showed a very high level of agreement for the expression of S100A4 (0.8, p<0.001). In the control group, none of oral mucosal tissues were positive for S100A4 in the cytoplasm of the epithelium. Out of 47 cases studied, 1/6 of stage I, 1/2 of stage II, 13/17 of stage III and 15/22 of stage IV cases showed positive S100A4 expression (Table 2). A strong association was noted between the stage of the tumor and the expression score of S100A4 (p=0.007). S100A4 expression was positive in 12/14 (85.7%) node positive stage III cases, of which 7/12 were (3+) and 5/12 were (2+) for S100A4 expression. Among the node negative cases, 1/3 cases showed (3+) for S100A4 expression. Likewise, S100A4 expression was positive in 14/15 (93.3%) stage IV cases, of which 13/14 were (3+) and 1/14 was (2+). Among the 7 node negative cases, 1/7 was (3+) and the remaining 6/7 cases were negative for S100A4 expression. Although the cytoplasmic expression of S100A4 was strongly associated with lymph node involvement (p<0.001), there was no association between S100A4 expression in lymph node positive cases and primary size of the tumor (p=0.15).
Table 2

Association of S100A4 expression with clinical stage, lymph node involvement, tumor size, metastasis, recurrence, grade of tumor and pattern of invasion

Parameters02+3+TotalChi-squarep value
Stage      
Stage I5106  
Stage II1102  
Stage III4581714.50.007
Stage IV711422  
Total1782247  
Lymphnode      
No80210  
Yes36202922.7<0.001
Total1162239  
Tumor Size      
T152411  
T225714  
T330148.70.15
T4711018  
Total1782247  
Metastasis      
No70411  
Yes01101110.710.004
Total711422  
Recurrence      
No1161128  
Yes00111111.40.002
Total1162239  
Grade      
WDSCC64515  
MDSCC849215.070.27
PDSCC30811  
Total1782247  
Pattern of invasion      
Type 12114  
Type 26208  
Type 36321127.4<0.001
Type 4C32712  
Type 4D001212  
Total1782247  

WDSCC - Well differentiated squamous cell carcinoma; MDSCC - Moderately differentiated squamous cell carcinoma; PDSCC - Poorly differentiated squamous cell carcinoma

Association of S100A4 expression with clinical stage, lymph node involvement, tumor size, metastasis, recurrence, grade of tumor and pattern of invasion WDSCC - Well differentiated squamous cell carcinoma; MDSCC - Moderately differentiated squamous cell carcinoma; PDSCC - Poorly differentiated squamous cell carcinoma With regard to distant metastasis (M), 11/22 (50%) cases in stage IV were positive for S100A4 expression, out of which 10/11 were (3+) and 1/11 was (2+) for S100A4 expression. A strong association could be established between the S100A4 expression in tumor cells and distant metastasis (p=0.004). Likewise, 11/47 (23.4%) cases that recurred after treatment were either in stage III (2/11) or stage IV (9/11). All these cases showed (3+) expression for S100A4. Among the stage III cases that recurred, one was node positive and the other was negative, whereas all the 9 stage IV cases that recurred were node positive. There was a strong positive association between the S100A4 expression and rate of recurrence (p=0.002). With regard to the pattern of invasion among the positive cases, 1/6 cases of stage I showed a type 1 (Figure 1) pattern and 1/2 cases in stage II showed type 2 (Figure 2) pattern. Out of the 13 stage III cases that showed positive S100A4 expression, 2 were type 1, 2 others were type 2, 3 were type 3 (Figure 3), 3 were type 4C (Figure 4) and 3 were type 4D (Figure 5). In the same manner, out of the 15 stage IV cases that showed positive S100A4 expression, 2 were type 3, 4 were type 4C and 9 were type 4D. There was a strong association (p<0.001) between S100A4 expression and pattern of invasion of OSCC. However, there was no association seen between the S100A4 expression and histological grade of the OSCC (p=0.27).
Figure 1

Oral squamous cell carcinoma (OSCC) showing type 1 well defined borderline pattern of invasion (S100A4, 20x)

Figure 2

Oral squamous cell carcinoma (OSCC) showing type 2 cord like pattern of invasion (S100 A4, 20x)

Figure 3

Oral squamous cell carcinoma (OSCC) showing type 3 pattern of invasion with groups of cells with no distinct borderline (S100A4, 20x)

Figure 4

Oral squamous cell carcinoma (OSCC) showing type 4C diffuse cord like pattern of invasion (S100A4, 20x)

Figure 5

Oral squamous cell carcinoma (OSCC) showing type 4D diffuse widespread pattern of invasion (S100A4, 20x)

Oral squamous cell carcinoma (OSCC) showing type 1 well defined borderline pattern of invasion (S100A4, 20x) Oral squamous cell carcinoma (OSCC) showing type 2 cord like pattern of invasion (S100 A4, 20x) Oral squamous cell carcinoma (OSCC) showing type 3 pattern of invasion with groups of cells with no distinct borderline (S100A4, 20x) Oral squamous cell carcinoma (OSCC) showing type 4C diffuse cord like pattern of invasion (S100A4, 20x) Oral squamous cell carcinoma (OSCC) showing type 4D diffuse widespread pattern of invasion (S100A4, 20x)

DISCUSSION

Oral cancer is one of the major cancers worldwide, with a low five-year survival rate that has not significantly changed over the past few decades[12]. Metastasis, which is responsible for 90% of the cancer associated mortality, is one of the poorly understood factors in cancer progression. An important step for the invasion and metastasis is the epithelial mesenchymal transition (EMT), a complex process induced by modifications of multiple pathways leading to a spectrum of epithelial cellular changes, including loss of polarity and cohesion, increased motility, and the acquisition of mesenchymal phenotype. EMT is critical for the invasion, progression, and metastasis in epithelial carcinogenesis[8]. Understanding the modulators of EMT may provide information of specific molecular targets. Metastasis promoting S100A4 is a typical representative of S100 family of Ca2+-binding multifunctional proteins with dual extra- and intracellular function[5]. The increased expression of the S100A4 in invasive front of the tumor suggests the pivotal role played by S100A4 in invasion of tumor cells into the surrounding matrix. The acquisition of invasive phenotype with altered pattern of adhesion is a result of E-cadherin down regulation by S100A4, which the tumor cells acquire[14]. S100A4 further influences cell-matrix adhesions by interacting with liprin [1 and masking their protein kinase C-mediated phosphorylation sites[17]. Inhibition of the liprin [1-lAR complex by S100A4 loosens cell adhesion and allows cell invasion. Cell invasion is also facilitated by matrix metalloproteinases (MMPs), as S100A4 causes metastasis not only by affecting the motility of cells but also by affecting its invasive properties through influencing the expression of MMPs and their endogenous inhibitors[2]. A positive correlation of the S100A4 and MMP2 expression in oesophageal squamous cell carcinoma has been reported[29]. S100A4 is located at the leading edge of migrating cells[15], where it induces the formation of fexible protrusions. Moreover, in the presence of a chemoattractant, S100A4 enhances directed migration. Directed migration is dependent on the interaction of S100A4 with myosin II-A. Thus, the S100A4-myosin II-A interaction does not only increase cell motility, but also enhances cell polarization and directed migration[19]. S100A4 also binds to the septins 2, 6 and 7, which play a central role in cytokinesis, cell polarity determination, cytoskeletal reorganization, and membrane dynamics10,[16]. Therefore, the S100A4septin interaction also contributes to the process of migration. S100A4 protein contributes to tumor angiogenesis by stimulating the motility of endothelial cells. S100A4 binds to annexin II on the endothelial surface, a complex that activates the tissue plasminogen activator, which in turn converts the plasminogen to plasmin, activating proMMPs. Active MMPs and plasmin together induce extracellular matrix remodelling and thereby facilitate angiogenesis[26]. Intracellular S100A4 also enhances angiogenesis by interacting with methionine aminopeptidase 2 (MetAP2)[6]. Ca2+-dependent binding of S100A4 to MetAP2 modulates the MetAP2 activity, which could promote endothelial growth and angiogenesis. This process of angiogenesis favors the metastasis of the tumor to the regional lymph nodes. Elevated S100A4 expression has shown to be the marker of metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma[23], prostate adenocarcinoma[9], colorectal cancer4,[18] and breast cancer[24]. A higher level of S100A4 expression has shown to correlate with auxillary lymph node metastasis and overall patient survival[24]. Evidence suggesting the role for S100A4 in HNSCC, especially in OSCC, is scarce. Elevated S100A4 as a prognostic factor in metastatic cases of OSCC was demonstrated by Moriyama-Kita, et al.[21] (2004).Our findings showing increased expression of S100A4 in cases with regional lymphnode involvement and metastasis further emphasizes the role of S100A4 in oral cancer patients with poor prognosis. The final step in the metastatic cascade is the migration of the cells to a distant site and secondary colonization. In our study we found a significant correlation with the elevated S100A4 expression and distant metastasis. This finding has been elucidated earlier in papillary thyroid carcinoma[30] and pancreatic cancer[22], in which poor outcome of patients was related to increased S100A4 expression coupled with decreased E cadherin expression. The increased expression of S100A4 in our study showed a significant correlation with the overall clinical stage of tumor, a finding that has been noted also in colorectal carcinoma[4] and pancreatic cancer[22]. However, no association could be drawn between the elevated S100A4 level and the primary tumor size or histological grading in our analysis. fhese findings are in agreement with Moriyama-Kita, et al.[21] (2004) in OSCC and Chen, et al.[3] (2014) in lung cancer cells, in which S100A4 was frequently overexpressed, irrespective of histological subtype. In our study a strong association between S100A4 expression and pattern of invasion could be elicited, with an increased expression noted in type 4C and type 4D pattern of invasion. Similar observations have been made in malignant melanomas where increased expression of S100A4 in the nodular variant was noted, linking this association to the pattern of invasion[1]. Significantly, our observation of high S100A4 expression with tumor recurrence is a novel finding. S100A4 has been identified as a candidate marker for maintaining the stemness in head and neck cancer initiating cells. S100A4 controls the Notch and PTEN/PI3K/Akt signaling pathways, which regulate the self-renewal and tumorigenicity of stem cells or cancer stem cells[20]. S100A4 signaling pathways thus play a major role in the maintenance of cancer initiating cell population and contribute for the tumor recurrence.

CONCLUSION

In summary, the data from our study adds weight to the growing body of evidence that S100A4 can be used to identify the subgroup of patients at high risk of metastasis and recurrence in OSCC cases, and that targeting S100A4 signaling might be a potential therapeutic target for increasing the patient survival.
  30 in total

1.  Characterization of the metastasis-associated protein, S100A4. Roles of calcium binding and dimerization in cellular localization and interaction with myosin.

Authors:  Edward J Kim; David M Helfman
Journal:  J Biol Chem       Date:  2003-05-19       Impact factor: 5.157

2.  S100A4 is frequently overexpressed in lung cancer cells and promotes cell growth and cell motility.

Authors:  Na Chen; Daisuke Sato; Yuriko Saiki; Makoto Sunamura; Shinichi Fukushige; Akira Horii
Journal:  Biochem Biophys Res Commun       Date:  2014-04-13       Impact factor: 3.575

3.  Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer.

Authors:  P S Rudland; A Platt-Higgins; C Renshaw; C R West; J H Winstanley; L Robertson; R Barraclough
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

4.  Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation.

Authors:  Christophe Rosty; Takashi Ueki; Pedram Argani; Marnix Jansen; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4.

Authors:  Hideya Endo; Keizo Takenaga; Takayuki Kanno; Hitoshi Satoh; Shigeo Mori
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

6.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

7.  Liprin beta 1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1).

Authors:  Marina Kriajevska; Margrethe Fischer-Larsen; Ejvind Moertz; Ole Vorm; Eugene Tulchinsky; Mariam Grigorian; Noona Ambartsumian; Eugene Lukanidin
Journal:  J Biol Chem       Date:  2001-12-07       Impact factor: 5.157

8.  Interaction of the S100A4 (Mts1) protein with septins Sept2, Sept6, and Sept7 in vitro.

Authors:  Yu A Koshelev; S L Kiselev; G P Georgiev
Journal:  Dokl Biochem Biophys       Date:  2003 Jul-Aug       Impact factor: 0.788

9.  Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma.

Authors:  Sanjay Gupta; Tajamul Hussain; Gregory T MacLennan; Pingfu Fu; Jigar Patel; Hasan Mukhtar
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

Review 10.  Intracellular and extracellular roles of S100 proteins.

Authors:  Rosario Donato
Journal:  Microsc Res Tech       Date:  2003-04-15       Impact factor: 2.769

View more
  7 in total

1.  S100A4 participates in epithelial-mesenchymal transition in breast cancer via targeting MMP2.

Authors:  Han Xu; Mengquan Li; Yue Zhou; Feng Wang; Xiangke Li; Liuxing Wang; Qingxia Fan
Journal:  Tumour Biol       Date:  2015-09-26

2.  Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.

Authors:  Guifeng Ma; Yan Sun; Shiwen Fu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Targeting miR-21 with AS-miR-21 suppresses aggressive growth of human tongue squamous cell carcinoma in vivo.

Authors:  Yin Wang; Yu Zhu; Pin Lv; Longjiang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  The role of miR-21 in proliferation and invasion capacity of human tongue squamous cell carcinoma in vitro.

Authors:  Yin Wang; Yu Zhu; Pin Lv; Longjiang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Attenuation of cancer-initiating cells stemness properties by abrogating S100A4 calcium binding ability in head and neck cancers.

Authors:  Li-Hao Cheng; Kai-Feng Hung; Tung-Fu Huang; Hsin-Pei Hsieh; Shu-Ying Wang; Chih-Yang Huang; Jeng-Fan Lo
Journal:  Oncotarget       Date:  2016-11-29

6.  Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.

Authors:  Susen Burock; Severin Daum; Ulrich Keilholz; Konrad Neumann; Wolfgang Walther; Ulrike Stein
Journal:  BMC Cancer       Date:  2018-03-15       Impact factor: 4.430

7.  The effects of HBXIP on the biological functions of tongue squamous cell carcinoma cells and correlation with PI3K/Akt.

Authors:  Xue Meng; Weixian Liu
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.